Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland. He completed his internship and residency in pediatrics at Boston Children’s Hospital. He did an allergy-clinical immunology fellowship at NIH, and is Board Certified in Pediatrics and Allergy-Immunology. He served as Assistant Chief of Allergy-Immunology at Walter Reed Army Medical Center and had an initial faculty appointment at the Uniformed Services University of Health Sciences.
In 1984, he returned to Cleveland and joined the faculty of Case Western Reserve as Chief of the Division of Allergy-Immunology at Rainbow, Babies and Children’s Hospital and he rose to Professor of Pediatrics, Pathology and General Medical Sciences (Oncology). In 2008, Dr. Berger joined CSL Behring, but he continues to hold a faculty appointment at Case. He served for more than 20 years in the US Army and Army Reserve, including commanding a hospital unit during the peace effort in former Yugoslavia, and retired from the Army as a Colonel.
Dr. Berger's research has focused on control of inflammatory responses and on antigen-antibody and complement interactions, particularly in primary immune deficiency diseases and cystic fibrosis. He has been a leader in research on the clinical use of immunoglobulins and played a key role in developing the use of portable pumps to give IgG subcutaneously. He has published more than 100 peer-reviewed papers on his research, as well as numerous chapters and review articles.
Dr. Berger is a Fellow of the American Academy of Allergy Asthma and Immunology, the American Pediatric Society, and the American Academy of Pediatrics. He has been elected to the American Society for Clinical Investigation and the Society for Pediatric Research, and has served as a Director of the American Board of Allergy and Immunology and on numerous FDA and NIH panels.
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has helped establish the role of intravenous immunoglobulin in the treatment of myasthenia gravis and the Guillain-Barré Syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy.
She has acted in an advisory capacity to Health Canada and the FDA. Dr Bril also serves as the Deputy Physician-in-Chief for Economic Affairs for the Department of Medicine at the University Health Network and Mount Sinai Hospital and Chair of the Economics committee. She is part of the Department of Medicine Executive Committee and helps administer this group of 300 physicians.
Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury. He is Professor of Neurology at Johns Hopkins University and Director of the Neurology EMG Laboratory at the Johns Hopkins Hospital. His clinical and research interests are peripheral neuropathies.
Prof. Cornblath has co-authored a book entitled Diagnosis and Management of Peripheral Nerve Disorders and written over 200 articles and chapters. He is Editor-in-Chief of the Journal of the Peripheral Nervous System, Secretary/ Treasurer of the Peripheral Nerve Society, a member of the Board of Directors of the GBS/CIDP Foundation International and the Foundation for Peripheral Neuropathy, and Chair of one of the Hopkins Institutional Review Boards.
Learn more about the features, symptoms, diagnosis, and treatment of GBS.
Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan. Dr. Donofrio is board certified in Neurology, Internal Medicine, EMG and Neuromuscular Disorders. He is Chief of the Neuromuscular Section and Director of the EMG lab at Vanderbilt.
Other duties include Directorship of the MDA Clinic and the ALS Clinic. He is a member of the Medical Advisory Committee of the GBS/CIDP International Foundation; Vanderbilt University Medical Center is a certified Center of Excellence for the GBS/CIDP International Foundation. Dr. Donofrio has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis, ALS, and muscle disorders. He is the author of the textbook entitled The Textbook of Peripheral Neuropathy published in April 2012 by Demos Medical.
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina. She is a graduate of the University of North Carolina at Chapel Hill School of Medicine and pursued a residency in Neurology at Northwestern University and a Neuromuscular fellowship at Harvard Medical School. Dr. Gable is board certified in Neurology, Electrodiagnostic Medicine and Neuromuscular Disorders.
Dr. Gable has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis and muscle disorders. Other duties include Directorship of the Neuromuscular Fellowship Program at Duke University.
Kenneth C. Gorson, M.D. is a Professor of Neurology in the Department of Neurology at St. Elizabeth’s Medical Center, Tufts University School of Medicine, in Boston. Dr. Gorson has published over 90 original peer-reviewed research articles, book chapters, and reviews pertaining to Guillain-Barre´ syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), paraprotein associated neuropathies, vasculitic neuropathy, and various other inflammatory and immune-mediated disorders of the peripheral nervous system. His clinical and research expertise extends to patients with neuropathies associated with diabetes, connective tissue disorders, and cancer, inherited peripheral neuropathies, and disorders of muscle, myasthenia gravis, and amyotrophic lateral sclerosis. Professor Gorson also has extensive expertise in the medical management of numerous chronic neuropathic and musculoskeletal pain disorders. He has been a principal investigator in several clinical research studies, including experimental treatment trials for CIDP, multifocal motor neuropathy, myasthenia gravis, diabetic neuropathy, painful neuropathies, and post-herpetic neuralgia. He has lectured widely to medical specialists and patient support groups on various topics in the field of neuromuscular diseases.
Dr. Gorson is the Chairman of the Global Medical Advisor Board for the GBS/CIDP Foundation international, the United States Principal Investigator and country coordinator for the International Guillain-Barre Outcome Study (IGOS) and also serves on the Steering Committee for IGOS, Secretary for the Inflammatory Neuropathy Consortium, serves on the editorial board for Muscle & Nerve, and is an active member of the American Academy of Neurology (AAN), American Association of Electrodiagnostic Medicine, and Peripheral Nerve Society, and has previously served on the sub-committee responsible for the selection of neuromuscular courses for the annual meeting of the Academy. He also served as a Councilor for the Neuromuscular Section for the AAN.
In his teaching capacity, Dr. Gorson has served as Director of the Tufts Neurology Residency Training Program and was responsible for resident candidate selection, and supervises the daily academic activities of the Neurology resident trainees. He is also an integral part of the teaching staff for the neurology and medical interns and residents at St. Elizabeth’s Medical Center and medical students from Tufts University School of Medicine.
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California. He received his BA from The Johns Hopkins University and his medical degree from Tulane University School of Medicine. He subsequently completed his neurology training at the University of Washington and neuromuscular diseases at the University of Texas, Southwestern Medical Center.
Dr. Katz is board certified in in Psychiatry and Neurology and specializes in the management and treatment of neuromuscular diseases such as CIDP, GBS, ALS, myasthenia gravis and multifocal motor neuropathy. He also sits on the medical advisory board of the Guillain-Barre CIDP Foundation International, California State Myasthenia Gravis Association and Myasthenia Gravis Association of America. He has authored over 80 publications, written 7 text book chapters and has participated in more than 23 Investigator Initiated Studies over the past 10 years, and has been national PI in several ALS trials. Notably among his many contributions, Dr. Katz has been the first author of several pioneering clinical papers that have focused on novel presentations which have become part of the neurological nomenclature including distal acquired demyelinating sensory polyneuorpathy (DADS), isolated neck extensor myopathy (INEM), multifocal acquired motor axonopathy (MAMA), and brachial amyotrophic diplegia (BAD).
Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology. He obtained his undergraduate and medical degrees at the University of British Columbia and did his residency in neurology at the University of Toronto where he was chief resident from 2006-7. He later completed fellowships in neuromuscular medicine and neurophysiology (EMG) at Stanford University, where he also obtained a Master’s degree in clinical epidemiology.
He has been on staff at the Ellen and Martin Prosserman Center for Neuromuscular Diseases at TGH since 2010, where he runs neuromuscular and EMG clinics, is active in training of neurology and physiatry residents / fellows and conducts clinical research. He is cross-appointed to Sick Kids Hospital where he coordinates a transition clinic for young adults with neuromuscular conditions. In 2014 he took over as fellowship program director at the University of Toronto for the Division of Neurology. He is Associate Editor for the Canadian Journal of Neurological Science and co-chair for research in the Canadian Neuromuscular Disease Network. He has a research focus in outcome measures and clinical trials in immune mediated neuromuscular junction disorders such as myasthenia gravis and neuropathies such as CIDP.
Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program. He is Director of the GBS-CIDP Foundation Center of Excellence at Cedars-Sinai. Prior to his move to California in 2013, he was Associate Chair of Neurology at Wayne State University where he had been for 19 years.
He has been on the Board of Directors of the Peripheral Nerve Society, and on the Steering Committee of the Inflammatory Neuropathy Consortium. He is on the Medical Advisory Boards of the GBS-CIDP Foundation and the Myasthenia Gravis Foundation. He has been involved as an investigator, steering committee member and DSMB member in clinical trials in a number of immune mediated disorders including CIDP, myasthenia gravis and multifocal motor neuropathy.
Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.
National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery. He trained in medicine at Emmanuel College, Cambridge and the Charing Cross and Westminster Hospitals Medical School. He worked at the Royal Brompton and Hammersmith Hospitals before receiving his specialist neurology training in the UK at Guy’s, King’s, St Thomas’ and Charing Cross Hospitals, Hurstwood Park Neurosciences Centre and Queen Square, and at the Johns Hopkins Hospital in Baltimore, USA. He was appointed to a Consultant position at NHNN in 2005.
Learn how an algorithm could be used to personalize dosing schedules for IVIg.
Orell Mielke is a board certified neurologist who completed his medical training at the University of Heidelberg and partly in Chelmsford, London and Porto Alegre, Brasil. He was trained in Neurology and Psychiatry at the University Hospital of Mannheim. Before moving to the pharmaceutical industry, he spent 14 months at the Cochrane Stroke Center at the Western General Hospital in Edinburgh, Scotland and authored several systematic reviews in the field of acute ischemic stroke.
He gained over 11 years of industry experience at the CRO Parexel, at the Biotechnical Company Biotest and a Plasma Company Biotest before moving to CSL Behring in 2011 where he leads the clinical development of Immunoglobulins in neurological and immunological indications in the function of a Global Program Director. He has authored and co-authored several neurological publications and is a member of the German Society of Neurologists.
Understand the time variations in response to IVIg therapy during the CIDP PRIMA Trial.
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring. He completed his medical training at the University of Casablanca in Morocco. He also has a Master of Biomedical and Physical Engineering of Health in the University of Saints-Pères, Paris, and Biostatistics for the Health and Biological Sciences in Pierre at Marie Curie University in Paris. Before joining the pharmaceutical industry he spent 3 years in Emergency department. He gained over 10 years of industry experience in Medical Affairs departments first in central nervous system and psychiatry and then, from 2010 he joined CSL Behring as a medical manager in immunology.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Dr. Zaeem Siddiqi, MD, PhD is an Associate Professor of Medicine (Neurology) at the University of Alberta and Director of the neuromuscular program. He specializes in the diagnosis and management of patients with complex neuromuscular and autonomic disorders. As an expert in electrodiagnosis of neuromuscular disorders he has regularly conducted physician-training workshops for Canadian Congress of Neurosciences, American Academy of Neurology, and American Association of Neuromuscular Diseases and Electrodiagnostic Medicine (AANEM).
He is involved in translational and clinical research in myasthenia gravis and has been the lead investigator in several national and international clinical trials in this disease. His work has optimized the use of intravenous immunoglobulin in various neuromuscular diseases in the rural regions of Northern Alberta and neighbouring provinces. Dr. Siddiqi has also served in an advisory capacity to Health Canada and chairs the News Science Editorial Board committee for the AANEM.
Learn how subcutaneous immunoglobulin provides the additional benefit of flexibility of home infusion in patients with neuromuscular disease.
Claudia Sommer is a Professor of Neurology at the University of Würzburg, Germany. She received training in psychiatry, neuropathology, experimental anesthesia, and neurology. At the University of Würzburg she serves as a consultant in neurology, organizes an outpatient clinic for patients with pain, and leads the Peripheral Nerve Laboratory. Professor Sommer’s research interests include: the role of cytokines in the pathophysiology of pain, improvement and standardization of diagnostics in neuropathies, and the pathophysiology of antibody-mediated diseases. She has written more than 150 original research papers and more than 100 reviews and book chapters, and has edited several books.
Professor Sommer is active in the development of national and international guidelines on treatment of peripheral neuropathies, nerve and skin biopsies, and treatment of fibromyalgia and neuropathic and facial pain. She is a reviewer for scientific journals and the German Research Foundation (DFG), and serves on the editorial boards of several scientific journals.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.